A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective ...

Soft tissue sarcomas are malignant tumors that form in the soft tissues of the body. What are the types, how are they diagnosed, and can they be treated?

Soft tissue sarcoma can start in muscle, blood vessels, and fibrous tissue in the leg. STS in the leg may cause a tender growing lump. Learn more here.

Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced Soft Tissue Sarcoma (STS ...

QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 ...

Despite the absence of pain signals, post-operative opioids control tachycardia and hypertension, highlighting the unique ...

When Danville High School student Sophia Osterbur, 15, and her friends would prepare to take the stage at their show choir competitions last school year, they had a unique ritual. “During show choir, ...

US biotech fund BVF Parners has sold its stake in drug developer Syntara, thus exiting all of its ASX life sciences exposures ...

QBiotics' CEO and Managing Director, Stephen Doyle commented, "We are delighted with the outcomes from Stage 1 of our Phase IIa Soft Tissue Sarcoma trial. Tigilanol tiglate met both its primary and ...

The trial enrolled 49 patients with mTLS-negative STS, including leiomyosarcoma (45%) and synovial sarcoma (18%). The ...